AP Biosciences Inc

AP Biosciences, Inc. researches and develops protein and antibody drugs for unmet medical needs. Its pipeline includes IBI302 in Phase III trials for neovascular age-related macular degeneration, AP505 in Phase I trials for solid tumors, and AP203 in Phase I trials for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinoma. AP402 and AP601 are in pre-clinical research for breast cancer and for lung, pancreatic, bladder, ovarian, and other solid tumors, respectively. The company has a strategic collaboration with Delos Capital to discover and develop novel immune-related drug candidates through early clinical proof of concept. Founded in 2013, AP Biosciences is based in Taipei, Taiwan.